Status:
COMPLETED
HFNC and Acute Hypercapnic Respiratory Failure
Lead Sponsor:
Argentinian Intensive Care Society
Conditions:
High Flow Oxygen Therapy
Acute Hypercapnic Respiratory Failure
Eligibility:
All Genders
18+ years
Brief Summary
High-flow nasal cannula (HFNC) enables delivering humidified gas at high-flow rates controlling the oxygen inspired fraction (FiO2). Its efficacy has been demonstrated in hypoxemic acute respiratory f...
Eligibility Criteria
Inclusion
- Moderate to very severe COPD patients (GOLD 2 to 4) over 18 years old admitted to the ICU with hypercapnic ARF (PaCO2\> 45 mmHg and respiratory acidosis \[pH ≥7.30\], with or without hypoxemia + one of the following: Respiratory Rate ≥25 cycles per minute, intercostal and / or supraclavicular recruitment, or thoraco-abdominal synchrony, no prior use of NIV)
Exclusion
- Patients less than 18 years old
- Mild COPD patients
- Absence of hypercapnia
- Kelly M Score \> 3
- Haemodynamic instability (despite fluid resuscitation)
- NIV or Invasive Mechanical Ventilation (IMV) (Need to use previously to HFNC)
- Contraindications to implement high-flow oxygen therapy.
Key Trial Info
Start Date :
August 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04109560
Start Date
August 1 2018
End Date
September 30 2019
Last Update
October 23 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanatorio Anchorena
CABA, Argentina, 1425